专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070224653A1 Methods for Modulating an Immune Response by Modulating Krc Activity 审中-公开
公开(公告)号：US20070224653A1
公开(公告)日：2007-09-27
申请号：US10578402
申请日：2004-11-03
申请人： Laurie Glimcher , Mohamed Oukka
发明人： Laurie Glimcher , Mohamed Oukka
IPC分类号： G01N33/53 , A61K49/00 , C12N5/06
CPC分类号： G01N33/6872 , G01N33/6893 , G01N2500/00
摘要： This invention demonstrates that KRC molecules have multiple important functions as modulating agents in regulating a wide variety of cellular processes including: inhibiting NFkB transactivation, increasing TNF-alpha induced apoptosis, inhibiting JNK activation, inhibiting endogenous TNF-alpha expression, promoting immune cell proliferation and immune cell activation (e.g., in Th1 cells and/or Th2), activating IL-2 expression e.g., by activating the AP-1 transcription factor, and increasing actin polymerization. The present invention also demonstrates that KRC interacts with TRAF. Furthermore, the present invention demonstrates that KRC physically interacts with the c-Jun component of AP-1 to control its degradation. The present invention also demonstrates that KRC is downstream of several lymphocyte membrane receptors, including TNFR, TCR and TGFβR. Upon TNFR signaling, KRC associates with the adaptor protein TRAF2 to inhibit NFKB and JNK-dependent gene expression. Upon TCR stimulation, KRC expression is rapidly induced and KRC physically associates with the c-Jun transcription factor to augment AP-1 dependent gene transcription. KRC knock-out (KO) T cells have impaired production of AP-1-dependent genes such as CD69 and IL-2. Upon TCR stimulation KRC also associates with the Th2-specific transcription factor GATA3, and T cells lacking KRC have impaired production of GATA3 dependent Th2 cytokines, IL-4, IL-5 and IL-13. Finally, upon TGFβ receptor signaling, KRC physically associates with the transcription factor SMAD3 to activate IgA germline transcription in B cells, since KRC KO B cells have impaired IgA production and germline Igα (GLα) gene transcription. Methods for identifying modulators of KRC activity are provided. Methods for modulating an immune response and KRC-associated disorders using agents that modulate KRC expression and/or activity are also provided.

2. 发明申请

US20070009918A1 Methods and compositions for regulating T cell subsets by modulating transcription factor activity 审中-公开
标题翻译：通过调节转录因子活性来调节T细胞亚群的方法和组合物
公开(公告)号：US20070009918A1
公开(公告)日：2007-01-11
申请号：US11284418
申请日：2005-11-21
申请人： Laurie Glimcher , I-Cheng Ho
发明人： Laurie Glimcher , I-Cheng Ho
IPC分类号： C12Q1/68 , G01N33/53 , A61K48/00
CPC分类号： A61K38/1709 , A01K2217/05 , A61K48/00 , C07K14/4702 , C07K14/52 , C07K14/5406 , C07K14/82 , C07K2319/00 , G01N33/505
摘要： Methods for modulating production of a T helper type 2 (Th2)-associated cytokine, in particular interleukin-4, by modulating the activity of a transcription factor, in particular the proto-oncoprotein c-Maf, that regulates expression of the Th2-associated cytokine gene are disclosed. Methods for modulating development of T helper type 1 (Th1) or T helper type 2 (Th2) subsets in a subject using agents that modulate transcription factor activity are also disclosed. The methods of the invention can further involve use of agents that modulate the activity of additional transcription factors that contribute to the regulation of Th1- or Th2-associated cytokines, such as a Nuclear Factor of Activated T cells (NF-AT) protein and/or an AP-1 family protein. Compositions for modulating Th2-associated cytokine production, recombinant expression vectors and host cells, as well as screening assays to identify agents that modulate c-Maf activity, are also disclosed.
摘要翻译：通过调节调节Th2相关表达的转录因子，特别是原癌蛋白c-Maf的活性来调节T辅助2型（Th2）相关细胞因子特别是白细胞介素-4的产生的方法公开了细胞因子基因。还公开了使用调节转录因子活性的试剂调节受试者中T辅助性1型（Th1）或T辅助2型（Th2）亚型的发展的方法。本发明的方法还可以包括使用调节有助于调节Th1或Th2相关细胞因子（例如活化T细胞核因子（NF-AT）蛋白）和/ 或AP-1家族蛋白。还公开了用于调节Th2相关细胞因子产生的组合物，重组表达载体和宿主细胞，以及用于鉴定调节c-Maf活性的药剂的筛选测定。

3. 发明申请

US20060099195A1 Tumor cells with increased immunogenicity and uses therfor 有权
标题翻译：肿瘤细胞具有增加的免疫原性，并使用其它药物
公开(公告)号：US20060099195A1
公开(公告)日：2006-05-11
申请号：US11313556
申请日：2005-12-20
申请人： Suzanne Ostrand-Rosenberg , Sivasubramanian Baskar , Laurie Glimcher , Gordon Freeman , Lee Nadler
发明人： Suzanne Ostrand-Rosenberg , Sivasubramanian Baskar , Laurie Glimcher , Gordon Freeman , Lee Nadler
IPC分类号： A61K48/00
CPC分类号： A61K39/0011 , A61K39/00 , A61K48/00 , A61K2039/5152 , A61K2039/5156 , A61K2039/5158 , C07K14/70532 , C07K14/70539
摘要： Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using an agent which induces or increases expression of a T cell costimulatory molecule on the tumor cell surface or by coupling a T cell costimulatory molecule to the tumor cell surface. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating-a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor. A method for specifically inducing a CD4+ T cell response against a tumor and a method for treating a tumor by modification of tumor cells in vivo are disclosed.
摘要翻译：公开了修饰以表达T细胞共刺激分子的肿瘤细胞。在一个实施方案中，共刺激分子是CD28 / CTLA4配体，优选B淋巴细胞抗原B7。通过使用诱导或增加T细胞共刺激分子在肿瘤细胞表面上的表达或通过将T细胞共刺激分子与T细胞共刺激分子的偶联的试剂，可以通过用编码T细胞共刺激分子的核酸转染来修饰本发明的肿瘤细胞肿瘤细胞表面。还公开了进一步修饰以表达MHC I类和/或II类分子或其中抑制MHC相关蛋白（不变链）的表达的肿瘤细胞。本发明的修饰的肿瘤细胞可用于治疗患有肿瘤的患者，预防或抑制肿瘤的转移性扩散或预防或抑制肿瘤复发的方法。公开了特异性诱导针对肿瘤的CD4 + T细胞应答的方法和通过体内修饰肿瘤细胞治疗肿瘤的方法。

4. 发明申请

US20060084118A1 T-bet compositions and methods of use thereof 有权
公开(公告)号：US20060084118A1
公开(公告)日：2006-04-20
申请号：US11291426
申请日：2005-11-30
申请人： Laurie Glimcher , Susanne Szabo
发明人： Laurie Glimcher , Susanne Szabo
IPC分类号： G01N33/53 , C07K16/46
CPC分类号： C07K14/4705 , A01K2217/05 , A61K38/00 , C07K2319/00 , G01N33/6866 , G01N33/6869 , G01N33/6872 , G01N33/6875 , G01N33/74 , G01N2500/00
摘要： Isolated nucleic acid molecules encoding T-bet, and isolated T-bet proteins, are provided. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a T-bet transgene. The invention further provides T-bet fusion proteins and anti-T-bet antibodies. Methods of using the T-bet compositions of the invention are also disclosed, including methods for detecting T-bet activity in a biological sample, methods of modulating T-bet activity in a cell, and methods for identifying agents that modulate the activity of T-bet.

5. 发明申请

US20070128661A1 Modulation of IL-2 production by T-bet 有权
标题翻译：通过T-bet调节IL-2产生
公开(公告)号：US20070128661A1
公开(公告)日：2007-06-07
申请号：US11593811
申请日：2006-11-07
申请人： Laurie Glimcher , Eun Hwang
发明人： Laurie Glimcher , Eun Hwang
IPC分类号： C40B30/06 , C40B40/04 , C40B40/10
CPC分类号： C12Q1/485 , G01N2333/4706 , G01N2333/55 , G01N2500/02
摘要： The instant invention is based, at least in part, on the dentification of a mechanism by which T-bet modulates IL2 production. The present invention pertains to methods of identifying agents that modulate the kinase-mediated interaction of T-bet with RelA, as well as methods of use therefore.
摘要翻译：本发明至少部分地基于T-bet调节IL2产生的机制的牙齿修复。本发明涉及鉴定调节T-bet与RelA的激酶介导的相互作用的试剂的方法以及因此使用的方法。

6. 发明申请

US20050026285A1 Methods for modulating an immune response by modulating KRC activity 有权
标题翻译：通过调节KRC活性来调节免疫应答的方法
公开(公告)号：US20050026285A1
公开(公告)日：2005-02-03
申请号：US10701401
申请日：2003-11-03
申请人： Laurie Glimcher , Mohamed Oukka
发明人： Laurie Glimcher , Mohamed Oukka
IPC分类号： G01N33/68 , A61K38/17 , A61K48/00
CPC分类号： G01N33/6872 , G01N33/6893 , G01N2500/00
摘要： This invention demonstrates that KRC molecules have multiple important functions as modulating agents in regulating a wide variety of cellular processes including: inhibiting NFkB transactivation, increasing TNF-alpha induced apoptosis, inhibiting JNK activation, inhibiting endogenous TNF-alpha expression, promoting immune cell proliferation and immune cell activation (e.g., in Th1 cells), activating IL-2 expression e.g., by activating the AP-1 transcription factor, and increasing actin polymerization. The present invention also demonstrates that KRC interacts with TRAF. Furthermore, the present invention demonstrates that KRC physically interacts with the c-Jun component of AP-1 to control its degradation Methods for identifying modulators of KRC activity are provided. Methods for modulating an immune response using agents that modulate KRC activity are also provided.
摘要翻译：本发明证明KRC分子在调节多种细胞过程中具有多种重要功能作为调节因子，包括：抑制NFkB反式激活，增加TNF-α诱导的凋亡，抑制JNK活化，抑制内源性TNF-α表达，促进免疫细胞增殖和免疫细胞活化（例如，在Th1细胞中），活化IL-2表达，例如通过激活AP-1转录因子和增加肌动蛋白聚合。本发明还表明，KRC与TRAF相互作用。此外，本发明表明KRC与AP-1的c-Jun组分物理相互作用以控制其降解提供了用于鉴定KRC活性调节剂的方法。还提供了使用调节KRC活性的试剂调节免疫应答的方法。

7. 发明申请

US20050004034A1 Human C-Maf compositions and methods of use therefor 审中-公开
标题翻译：人类C-Maf组合物及其使用方法
公开(公告)号：US20050004034A1
公开(公告)日：2005-01-06
申请号：US10923520
申请日：2004-08-20
申请人： Laurie Glimcher , John Douhan
发明人： Laurie Glimcher , John Douhan
IPC分类号： A01K67/027 , A61K38/00 , C07K14/82 , C07K16/18 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12Q1/68 , G01N33/15 , G01N33/50 , G01N33/53 , A61K38/17 , A61K48/00 , C07H21/04
CPC分类号： C07K14/82 , A01K2217/05 , A61K38/00 , C07K2319/00
摘要： Isolated nucleic acid molecules encoding human c-Maf, and isolated c-Maf proteins, are provided. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a human c-Maf transgene. The invention further provides human c-Maf fusion proteins and anti-human c-Maf antibodies. Methods of using the human c-maf compositions of the invention are also disclosed, including methods for detecting human c-Maf activity in a biological sample, methods of modulating human c-Maf activity in a cell, and methods for identifying agents that modulate the activity of human c-Maf.
摘要翻译：提供编码人c-Maf和分离的c-Maf蛋白的分离的核酸分子。本发明进一步提供反义核酸分子，含有本发明的核酸分子的重组表达载体，已经引入了表达载体的宿主细胞和携带人c-Maf转基因的非人转基因动物。本发明还提供人c-Maf融合蛋白和抗人c-Maf抗体。还公开了使用本发明的人c-maf组合物的方法，包括用于检测生物样品中人c-Maf活性的方法，调节细胞中人c-Maf活性的方法，以及用于鉴定调节人类c-Maf的活动。

8. 发明申请

US20080038235A1 Methods for regulating T cell subsets by modulating transcription factor activity 审中-公开
标题翻译：通过调节转录因子活性调节T细胞亚群的方法
公开(公告)号：US20080038235A1
公开(公告)日：2008-02-14
申请号：US11603292
申请日：2006-11-21
申请人： Laurie Glimcher , I-Cheng Ho
发明人： Laurie Glimcher , I-Cheng Ho
IPC分类号： A61K35/12 , A61P37/02 , C12N15/85 , C12N5/02
CPC分类号： G01N33/505 , A01K2217/05 , A61K38/00 , C07K14/4702 , C07K14/52 , C07K14/5406 , C07K14/82 , C07K2319/00
摘要： Methods for modulating production of a T helper type 2 (Th2)-associated cytokine, in particular interleukin-4, by modulating the activity of one or more transcription factors that cooperate with NF-AT family proteins to regulate expression of a Th2-associated cytokine gene are disclosed. In one embodiment, the activity of a maf family protein (e.g., c-Maf or a small maf protein, such as p18) is modulated. In another embodiment, the activity of a protein that interacts with an NF-AT family protein (e.g., NIP45) is modulated. Combination methods, for example wherein the activities of a maf family protein and an NF-AT protein are modulated or the activities of a maf protein and NF-AT-interacting protein are modulated, are also encompassed by the invention. Methods for modulating development of T helper type 1 (Th1) or T helper type 2 (Th2) subsets in a subject using agents that modulate transcription factor activity are also disclosed.
摘要翻译：通过调节与NF-AT家族蛋白质配合以调节Th2相关细胞因子表达的一种或多种转录因子的活性来调节T辅助2型（Th2）相关细胞因子特别是白细胞介素-4的产生的方法基因被公开。在一个实施方案中，调节maf家族蛋白（例如，c-Maf或小maf蛋白，例如p18）的活性。在另一个实施方案中，调节与NF-AT家族蛋白（例如NIP45）相互作用的蛋白质的活性。本发明还包括组合方法，例如其中maf家族蛋白和NF-AT蛋白的活性被调节或maf蛋白和NF-AT相互作用蛋白的活性被调节。还公开了使用调节转录因子活性的试剂调节受试者中T辅助性1型（Th1）或T辅助2型（Th2）亚型的发展的方法。

9. 发明申请

US20060223116A1 Modulation of Th2 lineage commitment by T-bet 审中-公开
标题翻译：通过T-bet调节Th2谱系承诺
公开(公告)号：US20060223116A1
公开(公告)日：2006-10-05
申请号：US11335927
申请日：2006-01-20
申请人： Laurie Glimcher , Susanne Szabo , Eun Hwang
发明人： Laurie Glimcher , Susanne Szabo , Eun Hwang
IPC分类号： C40B30/04 , C40B40/10
CPC分类号： G01N33/505 , A61K49/0008 , G01N2333/4706 , G01N2500/02
摘要： The instant invention is based, at least in part, on the identification of a mechanism by which T-bet directly modulates Th2 cytokine production. The present invention pertains to methods of identifying agents that modulate the Tec kinase-mediated interaction of T-bet with GATA-3, as well as methods of use therefore.
摘要翻译：本发明至少部分地基于T-bet直接调节Th2细胞因子产生的机制的鉴定。本发明涉及鉴定调节T-bet与GATA-3的Tec激酶介导的相互作用的试剂的方法以及因此使用的方法。

10. 发明申请

US20060068420A1 Regulation of Th2 cell activity by modulation of NFATp and NFAT4 activity 审中-公开
标题翻译：通过调节NFATp和NFAT4活性调节Th2细胞活性
公开(公告)号：US20060068420A1
公开(公告)日：2006-03-30
申请号：US11186400
申请日：2005-07-20
申请人： Laurie Glimcher , Ann Ranger , Mohamed Oukka
发明人： Laurie Glimcher , Ann Ranger , Mohamed Oukka
IPC分类号： C40B40/08 , C40B40/10
CPC分类号： G01N33/505 , A61K38/17 , C07K14/4702 , G01N2333/4703 , G01N2333/54
摘要： The invention demonstrates that NFATp and NFAT4 are required for the control of lymphocyte homeostasis and act as selective repressors of Th2 cells. The invention provides mice deficient in both NFATp and NFAT4 that exhibit a phenotype characteristic of increased Th2 cell activity. Methods for identifying modulators of Th2 cell activity, using either cells deficient in both NFATp and NFAT4, mice deficient in both NFATp and NFAT4, or indicator compositions containing both NFATp and NFAT4, are provided. Methods of regulating Th2 cell activity using agents that modulate the activity of NFATp and NFAT4 are also provided. Methods for diagnosing disorders associated with aberrant Th2 cell activity, by assessing changes in NFATp and/or NFAT4 expression, are also provided.
摘要翻译：本发明证明NFATp和NFAT4是控制淋巴细胞体内平衡所必需的，并且作为Th2细胞的选择性阻遏物。本发明提供缺乏NFATp和NFAT4的小鼠，其表现出Th2细胞活性增加的表型特征。提供了使用NFATp和NFAT4两者缺陷的细胞，NFATp和NFAT4两者缺陷的小鼠或含有NFATp和NFAT4两者的指示剂组合来鉴定Th2细胞活性调节剂的方法。还提供了使用调节NFATp和NFAT4的活性的试剂调节Th2细胞活性的方法。还提供了通过评估NFATp和/或NFAT4表达的变化来诊断与异常Th2细胞活性相关的障碍的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式